From Undruggable To Druggable: Activating Protein Phosphatase 2A, Rappta's New Approach To Cancer
Rappta Therapeutics Raises A Series A From VC Syndicate
Executive Summary
The development of first-in-class anticancers that activate protein phosphatase 2A is the aim of the Helsinki-headquartered Rappta Therapeutics. It has just raised €9m in a series A involving top-tier biotech VCs to move promising candidates towards the clinic.